Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings -- Rubio and Corell -- Evidence-Based Mental Health
Individuals with schizophrenia die ∼15–20 years prematurely compared to the general population, mostly due to cardiovascular disease, obesity-related cancer, diabetes and chronic obstructive pulmonary disease.1 Owing to the known metabolic effects of antipsychotics,2 clarifying their role in increased mortality is important. Paradoxically, prior studies in schizophrenia have suggested a relative decrement in mortality with moderate antipsychotic doses compared to no antipsychotic exposure. Cohort studies have indicated an elevated mortality risk with benzodiazepines in several populations, but adjustment for other treatment variables has been limited. To read the full article, log in using your NHS OpenAthens details.
